Henriquez-Figuereo, A. (Andreina)

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties
    (Elsevier, 2024) Sanmartin-Grijalba, C. (Carmen); Morán-Serradilla, C. (Cristina); Angulo-Elizari, E. (Eduardo); Plano-Amatriain, D. (Daniel); Henriquez-Figuereo, A. (Andreina)
    Cancer encompasses a group of pathologies with common characteristics, high incidence, and prevalence in all countries. Although there are treatments available for this disease, they are not always effective or safe, often failing to achieve the desired results. This is why it is necessary to continue the search for new therapies. One of the strategies for obtaining new antitumor drugs is the use of 1,4-naphthoquinone as a scaffold in synthetic or natural products with antitumor activity. This review focuses on compiling studies related to the antitumor activity of 1,4-naphthoquinone and its natural and synthetic derivatives over the last 10 years. The work describes the main natural naphthoquinones with antitumor activity and classifies the synthetic naphthoquinones based on the structural modifications made to the scaffold. Additionally, the formation of metal complexes using naphthoquinones as a ligand is considered. After a thorough review, 197 synthetic compounds with potent biological activity against cancer have been classified according to their chemical structures and their mechanisms of action have been described.
  • Thumbnail Image
    Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases
    (Elsevier, 2023) Sanmartin-Grijalba, C. (Carmen); Morán-Serradilla, C. (Cristina); Angulo-Elizari, E. (Eduardo); Plano-Amatriain, D. (Daniel); Henriquez-Figuereo, A. (Andreina)
    Neglected tropical diseases (NTDs) encompass a group of infectious diseases with a protozoan etiology, high incidence, and prevalence in developing countries. As a result, economic factors constitute one of the main obstacles to their management. Endemic countries have high levels of poverty, deprivation and marginalization which affect patients and limit their access to proper medical care. As a matter of fact, statistics remain un- collected in some affected areas due to non-reporting cases. World Health Organization and other organizations proposed a plan for the eradication and control of the vector, although many of these plans were halted by the COVID-19 pandemic. Despite of the available drugs to treat these pathologies, it exists a lack of effectiveness against several parasite strains. Treatment protocols for diseases such as American trypanosomiasis (Chagas disease), leishmaniasis, and human African trypanosomiasis (HAT) have not achieved the desired results. Un- fortunately, these drugs present limitations such as side effects, toxicity, teratogenicity, renal, and hepatic impairment, as well as high costs that have hindered the control and eradication of these diseases. This review focuses on the analysis of a collection of scientific shreds of evidence with the aim of identifying novel chalcogen- derived molecules with biological activity against Chagas disease, leishmaniasis and HAT. Compounds illustrated in each figure share the distinction of containing at least one chalcogen element. Sulfur (S), selenium (Se), and tellurium (Te) have been grouped and analyzed in accordance with their design strategy, chemical synthesis process and biological activity. After an exhaustive revision of the related literature on S, Se, and Te compounds, 183 compounds presenting excellent biological performance were gathered against the different causative agents of CD, leishmaniasis and HAT.
  • Thumbnail Image
    Next generation of selenocyanate and diselenides with upgraded leishmanicidal activity
    (Elsevier, 2023) Alcon, M. (Mercedes); Sanmartin-Grijalba, C. (Carmen); de-Lucio, H. (Héctor); Moreno, E. (Esther); Plano-Amatriain, D. (Daniel); Jiménez-Ruiz, A. (Antonio); Espuelas, S. (Socorro); Henriquez-Figuereo, A. (Andreina)
    Nowadays, leishmaniasis is still treated with outdated drugs that present several obstacles related to their high toxicity, long duration, parenteral administration, high costs and drug resistance. Therefore, there is an urgent demand for safer and more effective novel drugs. Previous studies indicated that selenium compounds are promising derivatives for innovative therapy in leishmaniasis treatment. With this background, a new library of 20 selenocyanate and diselenide derivatives were designed based on structural features present in the leishmanicidal drug miltefosine. Compounds were initially screened against promastigotes of L. major and L. infantum and their cytotoxicity was evaluated in THP-1 cells. Compounds B8 and B9 were the most potent and less cytotoxic and were further screened for the intracellular back transformation assay. The results obtained revealed that B8 and B9 showed EC50 values of 7.7 µM and 5.7 µM, respectively, in L. major amastigotes, while they presented values of 6.0 µM and 7.4 µM, respectively, against L. infantum amastigotes. Furthermore, they exerted high selectivity (60 < SI > 70) towards bone marrow-derived macrophages. Finally, these compounds exhibited higher TryR inhibitory activity than mepacrine (IC50 7.6 and 9.2 µM, respectively), and induced nitric oxide (NO) and reactive oxygen species (ROS) production in macrophages. These results suggest that the compounds B8 and B9 could not only exert a direct leishmanicidal activity against the parasite but also present an indirect action by activating the microbicidal arsenal of the macrophage. Overall, these new generation of diselenides could constitute promising leishmanicidal drug candidates for further studies.
  • Thumbnail Image
    Exploring novel Se-compounds as promising therapeutical option for leishmaniasis management
    (Universidad de Navarra, 2023-12-14) Henriquez-Figuereo, A. (Andreina); Sanmartin-Grijalba, C. (Carmen); Plano-Amatriain, D. (Daniel)
    Globally, more than one billion people are affected by neglected tropical diseases (NTDs). The control, treatment, and elimination of NTDs, which mainly affect socio-economically disadvantaged regions, is one of the crucial obstacles for these countries to achieve health equity1 . Leishmaniasis is a NTD and the second leading cause of death from parasites in the world. Between 700,000 and 1 million new cases are reported worldwide each year. Treatment remains a challenge and still relies on compounds with toxic side effects. More than 20 parasite species cause leishmaniasis, making difficult the use of the same treatment regimens in multiple regions. There is no universal treatment for leishmaniasis2,3 . For many decades, most patients have been treated with intravenous or intramuscular injections of antimonials as first-line treatment. The use of antimonials is associated with life-threatening side effects, including damage to the heart, liver, and pancreas. In addition, treatments vary between regions and depend on the form of leishmaniasis, the causative parasite, the immune status of the patient and the local availability of therapy. Therefore, new treatments for leishmaniasis are urgently needed4 . Selenium (Se) is a metalloid of the chalcogen group. Se is among the essential trace elements because of its key role in cellular and thyroid metabolism, fertility, immune function, protection against oxidative damage and other vital functions5 . Se is acquired through the diet in two main forms: selenocysteine, found mostly in animal foods, and selenomethionine, found in plant products. Dietary Se-compounds differ in their metabolism and ability to produce different metabolites. The biological activity of Se-compounds is exerted via their metabolites. Therefore, the routes by which each compound is metabolized, and the relative abundance of each metabolite are related to their efficacy in the prevention and treatment of different diseases6 . Se plays a key role in the immune response against leishmaniasis, a disease caused by the Leishmania parasite7 . Low Se levels are associated with more severe forms of the disease, due to reduced antioxidant enzyme activity and increased oxidative stress. This suggests that Se is important in the pathophysiology of leishmaniasis, and its deficiency may aggravate Leishmania infection8 . The scientific literature is not abundant in relation to the development of new organic compounds derived from Se for the treatment of leishmaniasis. Studies have shown the antioxidant, antiviral, and anticancer properties of Se, it has been incorporated into antimicrobial nanomaterials for the treatment of Leishmania strains, with promising results, so it can be considered as an attractive novel therapeutic agent. As a consequence of the problems shown by drugs for the treatment of leishmaniasis, research into newly synthesized compounds that improve these limitations is necessary. For this reason, the aim of this Memory entitled: "Exploring novel se-compounds as promising therapeutical option for leishmaniasis management", is to provide an advance in the knowledge of a type of structures that can contribute as promising therapeutic agents for this disease. Our research group has more than 10 years of experience in the synthesis and biological evaluation of new synthesized Se-derivatives, which presented superior levels of activity and selectivity than reference drugs currently used in clinic. The chemical compounds presented in this Ph.D. project are newly synthesized and have been developed by means of a rational design and starting from economically accessible reagents. The structure of these compounds is characterized by their simplicity, being compounds mostly of low molecular weight, with molecular symmetry, and the presence of at least one Se atom in different functional groups. In some cases, the sulfur (S) analog has been synthesized, with the aim of evaluating the importance of the Se atom in the biological activity of the compounds. The results obtained during the development of this research project were grouped into Chapters I, II, and III.